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Introduction
Secretion of microbicidal and histotoxic molecules by
polymorphonuclear leukocytes (PMNs) stimulated by
soluble, physiological agonists depends on the cells
receiving 2 signals (1). Ligation of integrins informs the
cells that they have made multiple contacts with extra-
cellular matrix proteins in the tissues. The second sig-
nal is delivered through receptors for inflammatory
cytokines, chemokines, eicosanoids, glyceryl ethers,
formyl peptides, or activated complement. These
responses not only underlie antimicrobial defense but
contribute to tissue damage in such states as septic
shock, respiratory distress syndrome, ischemia-reper-
fusion, and rheumatoid arthritis. Thus, understanding
how PMNs integrate the components of the binary sig-
nals controlling their activation may hold a key to new
anti-inflammatory therapies.
TNF is a powerful mediator of the innate immune
response. Despite intense interest in TNF signaling, it
remains unclear how TNF activates PMNs. Most stud-
ies of signal transduction through TNF receptors
have dealt with gene expression, cell proliferation, or
apoptosis, mostly in transformed cell lines. In primary
PMNs, however, TNF elicits spreading, exocytosis,
and a respiratory burst independently of transcrip-
tion and translation (2). No role in these responses
has been described for any of the proteins thus far
known to be associated with the intracellular
domains of TNF receptors.
In vitro, TNF-treated PMNs spread on matrix pro-
tein-coated surfaces (3) and tyrosine phosphorylate sev-
eral focal adhesion proteins (4, 5). The latter include
paxillin (4, 6) and the tyrosine kinases fgr (7), lyn (8),
and syk (9). When spreading is advanced, the cells
abruptly begin to release H2O2 and granule contents
(10) at a maximal rate (2, 3).
Protein tyrosine phosphorylation is necessary for the
respiratory burst of adherent PMNs (5). PMNs from
mice rendered genetically deficient in either of 2 src-
family tyrosine kinases, fgr or hck, responded to TNF
normally, but PMNs from mice doubly deficient in fgr
and hck neither spread nor secreted oxidants in
response to TNF (11). However, further studies strong-
ly suggested that activation of fgr is not essential for
the integrin- and TNF-dependent respiratory burst in
human PMNs. On the contrary, activation of fgr and
lyn in human PMNs appears to be a consequence,
rather than a cause, of the respiratory burst (12). As
yet, there has been no identification of any specific
tyrosine kinase whose activity is required for the
cytokine-induced, adhesion-dependent respiratory
burst of human PMNs.
Tyrosine phosphoproteins in TNF-stimulated,
adherent human PMNs were localized to punctate
structures on the adhering surface containing vin-
culin, a marker of focal adhesions (6). This observa-
tion directed our attention to tyrosine kinases asso-
ciated with such structures. Among the tyrosine
kinases localized to focal adhesions and involved in
integrin signaling are the focal adhesion kinases,
whose prototype is FAK (13). FAK is activated after b 1
and b 3 integrin stimulation in fibroblasts and
platelets and binds b 1 and b 3 integrins, src, CSK, pax-
illin, GRAF, Cas, phosphatidylinositol 3-kinase
(PI3K), and sos/Grb2 (reviewed in ref. 14). Human
PMNs contain FAK, but its tyrosine phosphorylation
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is not altered by adhesion (6, 15) or TNF stimulation
(6), although spontaneous spreading on laminin pro-
motes it (15).
Recently, a second member of the FAK family has
been identified, termed pyk2 (proline-rich tyrosine
kinase) (16), CAKb (17), and RAFTK (18). Pyk2 is more
prominent than FAK in unseparated peripheral blood
leukocytes. Although pyk2 and FAK are highly homol-
ogous, the amino acid sequences surrounding the con-
served tyrosines are not identical, suggesting that
pyk2’s binding partners, including the src kinases that
activate it, may be different than FAK’s. Indeed, in cells
possessing both kinases, one but not the other is acti-
vated by a given stimulus (19, 20). Pyk2 is activated by
TNF in HL-60 leukemic cells (21) but has not been
identified in primary PMNs.
The present study demonstrates pyk2 in primary
human PMNs; localizes it to focal adhesions and
podosomes; and demonstrates its tyrosine phospho-
rylation, activation, and association with paxillin dur-
ing activation of the cells by TNF. Of 51 chemically
distinct tyrosine kinase inhibitors tested, 1 was a par-
ticularly potent and selective inhibitor of the TNF-
induced respiratory burst. This agent, tyrphostin A9,
also inhibited the tyrosine phosphorylation of pyk2.
Wortmannin, a PI3K inhibitor, also blocked pyk2
phosphorylation, while leaving most tyrosine phos-
phorylation intact. Thus, pyk2 appears to play an
essential role in the ability of PMNs to integrate sig-
nals from b 2 integrins and TNF receptors, and partic-
ipates in a signal cascade of interest as a potential tar-
get for anti-inflammatory therapy.
Methods
PMNs and test agents. Human PMNs were isolated from
heparinized blood of normal donors and processed as
described for immunoprecipitation (6), immunoblot
(6), microscopy (1), H2O2 release (3), and bactericidal
function (22). Pure recombinant human TNF was a gift
of Genentech Inc. (South San Francisco, California,
USA) PMA was from Sigma Chemical Co. (St. Louis,
Missouri, USA). Tyrosine kinase inhibitors and wort-
mannin were obtained from Calbiochem-Nov-
abiochem Corp. (San Diego, California, USA) or from
Samuel Wright at Merck Research Laboratories (Rah-
way, New Jersey, USA), where they were assembled from
commercial sources.
Immunoprecipitation, immunoblot, and immunocyto-
chemistry. Rabbit anti-pyk2 antibody was a gift of H.
Avraham (Harvard Institute of Medicine, Boston,
Massachusetts, USA) (18) and was also purchased
from Upstate Biotechnology Inc. (Lake Placid, New
York, USA). Goat anti-PYK2 was from Santa Cruz
Biotechnology Inc. (Santa Cruz, California, USA).
Rabbit anti-phosphotyrosine antibody, mouse anti-
phosphotyrosine mAb (PY20-IgG2b), recombinant
mouse anti-phosphotyrosine mAb coupled to horse-
radish peroxidase (RC20), and anti-paxillin (349-
IgG1) mAb were from Transduction Laboratories
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Figure 1
Identification of pyk2 in human PMNs and its localization to adhe-
sion structures. (a) Pyk2 is evident only in PMNs treated with diiso-
propylfluorophosphate before lysis (first 2 lanes), in addition to the
other protease inhibitors used in the second 2 lanes (see text).
PMNs were plated on FBS-coated plates and treated with buffer
alone (control; C) or TNF (250 ng/mL; T) for 60 minutes. Identical
amounts of protein (100 m g) were loaded in each lane. (b) Indirect
immunofluorescence. PMNs adherent to FBS-coated glass cover-
slips were stimulated with TNF (100 ng/mL) for 60 minutes, fixed,
permeabilized, and stained with rabbit anti-pyk2 antibody (panel 1)
or mouse anti-vinculin mAb (panel 2), followed by Cy3-conjugated
donkey anti-rabbit (panels 1 and 3) or Cy2-conjugated donkey anti-
mouse IgG (panels 2 and 4). In panel 3, primary antibody was omit-
ted. In panel 4, an irrelevant mAb was used. The photomicrograph
is focused at the plane of cell contact with the substratum. (c) Con-
focal microscopy of cells prepared as in b and stained with rabbit
anti-pyk2 antibody (panel 5) or mouse anti-vinculin mAb (panel 6).
Sum of four 0.32-m m-thick images taken from the plane of contact
with the substratum.
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(Lexington, Kentucky, USA). Anti-vinculin mAb
(hVIN-1-IgG1) was from Sigma Chemical Co.
Immunoprecipitation and immunoblot were as
reported (6), including pretreatment with 5 mM diiso-
propylfluorophosphate, except that for coimmuno-
precipitation, cells were lysed in 200 m L of nondena-
turing modified RIPA buffer (10 mM Tris-HCl [pH 7.5],
1% Triton X-100, 150 mM NaCl, 1 mM sodium vana-
date, 0.1 mM sodium molybdate, 1 mM sodium
pyrophosphate, 1 mM NaF, 1 mM phenylmethylsul-
fonyl fluoride, and 5 m g/mL each of pepstatin A, leu-
peptin, aprotinin, and chymostatin) on ice for 30 min-
utes. A Bio-Rad MRC600 laser scanning confocal
microscope (Bio-Rad Microscience, Cambridge, Mass-
achusetts, USA) with 2 photomultiplier tubes was used
on an inverted Zeiss Axiovert microscope (Zeiss,
Oberkochen, Germany) with a · 63 (NA 1.4) Zeiss Plan-
apo objective for simultaneous detection of Cy2- and
Cy3-conjugated antibodies. Images were processed
with Metamorph software (Universal Image Corp.,
West Chester, Pennsylvania, USA).
Kinase assay. After immunoprecipitation with goat or
rabbit anti-pyk2 antibodies, immune complexes were
further washed in kinase buffer (25 mM HEPES, 1 mM
DTT, 10 mM MnCl2, 5 m M ATP [pH 7.4]) and then
incubated for 30 minutes at room temperature in
kinase buffer supplemented with [ g -32P]ATP (0.1 m Ci,
10 Ci/mmol). Proteins were separated on SDS-PAGE
gels, transferred electrophoretically to PVDF mem-
brane, and autoradiographed.
Results
Identification and localization of pyk2 in human PMNs. Pyk2
was detected by immunoblot in preparations contain-
ing more than 98% PMNs, but only when the cells were
treated before cell lysis with diisopropylfluorophos-
phate. Other protease inhibitors (phenylmethylsulfonyl
fluoride, pepstatin A, leupeptin, aprotinin, and chymo-
statin in combination) were unable to preserve pyk2
(Figure 1a). Thus, protease sensitivity may explain why
pyk2 was not identified previously in primary PMNs.
In adherent PMNs, phosphotyrosine-containing
proteins are predominantly localized in punctate
podosomes (23) abutting the cell surface in contact
with the subjacent matrix. The distribution of pyk2 in
primary human PMNs was consistent with localiza-
tion both to podosomes and to oblong structures at
the cell periphery, typical of focal adhesions (Figure 1,
b and c). Pyk2 colocalized with vinculin, a component
of focal adhesions. Pyk2 in both sets of structures was
confined to the cell surface in contact with the sub-
stratum (Figure 1b), as confirmed by confocal
microscopy (Figure 1c).
TNF-dependent tyrosine phosphorylation of pyk2. Stimu-
lation of adherent PMNs with TNF causes a time-
dependent increase in tyrosine phosphorylation of
proteins with an apparent Mr of ~ 120 kDa, compati-
ble with pyk2 (5). When PMNs adherent to fibrinogen-
coated or FBS-coated plates were stimulated with TNF
for 60 minutes, immunoprecipitation with anti-pyk2
followed by immunoblot with anti-phosphotyrosine
antibody demonstrated TNF-dependent tyrosine
phosphorylation of pyk2 (Figure 2a). Similar amounts
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Figure 2
TNF-stimulated tyrosine phosphorylation of pyk2. (a) PMNs were
plated on fetal bovine serum–coated (FBS) or fibrinogen-coated
(FBG) plates and treated with buffer alone (control; C) or TNF (250
ng/mL; T) for 60 minutes (FBS) or 30 minutes (FBG). Cell lysates
(200 m g) were immunoprecipitated (IP) with anti-pyk2 goat anti-
body. Proteins were separated by reducing SDS-PAGE, transferred to
nitrocellulose, and Western blotted (WB) with horseradish peroxi-
dase–conjugated (HRP-conjugated) anti-phosphotyrosine mAb fol-
lowed by enhanced chemiluminescence (ECL) detection. (b) PMNs
were plated on FBS-coated plates and treated with buffer alone (con-
trol; C) or TNF (250 ng/mL; T) for 20, 40, or 60 minutes as indicat-
ed. Cell lysates (500 m g) were immunoprecipitated (IP) with anti-
phosphotyrosine mAb. Proteins were separated by reducing
SDS-PAGE, transferred to nitrocellulose, and Western blotted (WB)
with anti-pyk2 antibody followed by ECL detection. Molecular mass
markers are indicated in kilodaltons.
Figure 3
Activation of pyk2 by TNF.
PMNs plated on FBS-coat-
ed dishes were treated with
buffer alone (control; C) or
TNF (250 ng/mL; T) for 60
minutes. PMNs were lysed
in modified RIPA buffer.
Lysates (200 m g) were
immunoprecipitated with
anti-pyk2 antibody, and the
immunoprecipitates were
subjected to in vitro kinase assay, separated on reducing SDS-PAGE,
transferred to a nylon membrane, and autoradiographed. Promi-
nent species are marked by arrows, including IgG heavy chain (h.c.).
Molecular mass markers are indicated in kilodaltons.
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of pyk2 were precipitated in all samples (data not
shown). No tyrosine phosphorylation of pyk2 was
detected in suspended PMNs treated or not with TNF
(data not shown). TNF-dependent tyrosine phospho-
rylation in adherent PMNs was shown to involve b 2
integrins (6, 7). Because b 2 integrins are the only
known receptors for fibrinogen in PMNs (24), it
appears that the dependence on b 2 integrins extends
to signaling for pyk2 phosphorylation.
Lysates of PMNs stimulated with TNF for various
times were next immunoprecipitated with anti-phos-
photyrosine antibody and immunoblotted with anti-
pyk2. Tyrosine phosphorylation of pyk2 was detectable
at 20 minutes, intense at 40 minutes, and still marked
by 60 minutes, compatible with the time course of
TNF-induced spreading (3) (Figure 2b).
Activation of pyk2 by TNF. PMNs were lysed with non-
denaturing buffer after a 60-minute incubation with or
without TNF. Anti-pyk2 immunoprecipitates were
washed, incubated in kinase buffer in the presence of
[ g -32P]ATP, separated by SDS-PAGE, transferred to a
PVDF membrane, and subjected to autoradiography
(Figure 3). The 2 species to undergo the most promi-
nent increase in incorporation of [ g -32P]ATP had Mr’s
compatible with pyk2 and IgG heavy chain. Addition-
al species undergoing TNF-triggered phosphorylation
had apparent Mr’s of ~ 150, 70, 45, and 34 kDa. Similar
amounts of pyk2 were precipitated in the 2 samples
(data not shown). These experiments showed that pyk2
becomes more enzymatically active when PMNs are
treated with TNF and/or associates with an active
kinase in response to TNF.
TNF-induced association of pyk2 with paxillin. A major sub-
strate to become tyrosine- and serine- or threonine-phos-
phorylated in PMNs in response to TNF is the focal
adhesion protein paxillin (6). Paxillin can bind FAK (25)
or pyk2 (26–30) by an interaction that is phosphotyro-
sine independent (25). In the previous experiment,(Fig-
ure 3), a protein with an Mr of ~ 70 kDa was immuno-
precipitated with pyk2 from lysates of TNF-treated
PMNs and phosphorylated in vitro, consistent with the
Mr of paxillin. We therefore immunoprecipitated PMNs
lysates with anti-pyk2 antibody and immunoblotted
with anti-paxillin mAb. A small amount of paxillin was
associated with pyk2 in control PMNs; the amount
increased markedly upon stimulation by TNF (Figure
4a). The high apparent Mr of pyk2-associated paxillin
suggested that both in basal and stimulated conditions,
this fraction of paxillin was heavily phosphorylated, as
previously documented for about 5% of paxillin in total
lysates of TNF-treated PMNs (6). Results were the same
when lysates were immunoprecipitated with anti-pax-
illin and immunoblotted with anti-pyk2 (Figure 4b).
Screening of a panel of tyrosine kinase inhibitors. Next, we
tested a series of tyrosine kinase inhibitors for their
ability to prevent the TNF-induced respiratory burst
while sparing the respiratory burst triggered by the
phorbol ester PMA. In dose-response fashion, we indi-
vidually tested 51 structurally diverse compounds
(Table 1) known to inhibit a variety of tyrosine kinases.
Fourteen failed to exert more than 50% suppression of
either the TNF- or PMA-induced respiratory burst up
to the highest concentration of compound tested (7.7
m M). Another 10 were inhibitory but blocked the
responses to TNF and to PMA equally, suggesting that
they affected a shared pathway, were toxic, or interfered
with the assay. Four were inhibitory for TNF response
at higher concentrations than for PMA. Twenty-three
inhibited the TNF response by more than 50% at or
below 8 m M, and either did not inhibit the response to
PMA or did so at a substantially higher concentration
than required to inhibit the response to TNF. The 9
most selective compounds from the last group (i.e.,
most potent against the response triggered by TNF and
least potent against the response triggered by PMA)
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Figure 4
TNF-enhanced association of pyk2 with paxillin. (a) Coimmunopre-
cipitation of paxillin with pyk2. PMNs plated on FBS-coated dishes
were treated with buffer alone (control; C) or TNF (250 ng/mL; T)
for 60 minutes. PMNs were lysed in modified RIPA buffer. Lysates
were immunoprecipitated (IP) with the indicated antibodies or with
protein A-Sepharose beads alone, separated on reducing SDS-PAGE,
transferred to nitrocellulose, and Western blotted (WB) with anti-
paxillin mAb followed by anti-mouse HRP-conjugated antibody with
ECL detection. Molecular mass markers are indicated in kilodaltons.
(b) Coimmunoprecipitation of pyk2 with paxillin. PMNs plated on
FBS-coated dishes were treated with buffer alone (control; C) or TNF
(250 ng/mL; T) for 60 minutes and lysed in modified RIPA buffer.
Lysates were immunoprecipitated with anti-paxillin mAb, separated
on reducing SDS-PAGE, transferred to nitrocellulose, and Western
blotted (WB) with anti-paxillin mAb or anti-pyk2 antibody followed
by anti-mouse or anti-goat HRP-conjugated antibodies with ECL
detection. Molecular mass markers are indicated in kilodaltons.
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were further tested by adding them to PMNs 30 min-
utes in advance of TNF or PMA, which improved the
apparent potency of several. Of these, tyrphostin A9
was the compound with the lowest IC50 for TNF (40
nM) and the greatest ratio between the IC50 for PMA
and that for TNF (106-fold) (Figure 5a). Lack of toxic-
ity of tyrphostin A9 and selectivity of its actions were
illustrated not only by its sparing of the response to
PMA over the concentration range 30 nM–2.6 m M, but
also by the lack of effect on the ability of PMNs to
ingest and kill Salmonella typhimurium (Figure 5b).
Inhibition of pyk2 phosphorylation by tyrphostin A9. A con-
centration of tyrphostin A9 that totally suppressed the
TNF-induced respiratory burst while sparing the PMA-
induced respiratory burst decreased the overall level of
protein tyrosine phosphorylation stimulated by TNF
in adherent cells. TNF-induced tyrosine phosphoryla-
tion of pyk2 was completely suppressed (Figure 5c).
Inhibition of pyk2 phosphorylation by wortmannin and PP2.
The most potent inhibitor of the TNF-induced respira-
tory burst identified in previous work was wortmannin
(31), an antagonist of PI3K. We wanted to determine
what relation wortmannin’s actions might have to the
pathway involving pyk2. When added before or together
with TNF, wortmannin inhibited H2O2 production with
an IC50 of 0.8 ± 0.1 nM (mean ± SEM), whereas PMA-
induced H2O2 release was unaffected (data not shown),
demonstrating wortmannin’s lack of toxicity. Delayed
addition of 10 nM wortmannin still resulted in complete
inhibition of H2O2 production triggered by previously
added TNF, provided that the drug was added during the
lag period characteristic of the response to TNF (2). Once
the lag period had expired, addition of wortmannin had
markedly less or no effect on the ongoing secretion of
H2O2  (Figure 6a). Thus, a wortmannin-sensitive process
was essential for initiating the respiratory burst in
response to TNF, but not for maintaining it.
Next, we tested the effect of wortmannin of pyk2
phosphorylation, comparing it with the most selective
src-family tyrosine kinase inhibitor commercially avail-
able — PP2 (32). Wortmannin (10 nM) had little effect
on the overall level of protein tyrosine phosphorylation
stimulated by TNF in adherent cells. Only 2 Mr classes
of polypeptides ( ~ 125 and ~ 95 kDa, respectively)
seemed to be affected (Figure 6b, top). Strikingly, how-
ever, tyrosine phosphorylation of pyk2 was completely
abolished (Figure 6, bottom). In contrast, PP2 at much
higher concentrations (2.5 m M) blocked almost all
detectable tyrosine phosphorylation, including that of
pyk2 (Figure 6b). Similar amounts of pyk2 were pre-
cipitated in each case (data not shown). These findings
suggest that pyk2 participates in the signaling cascade
leading to the respiratory burst in TNF-treated, adher-
ent PMNs and that PI3K activity is required upstream
of pyk2 activation. These results are also consistent
with a role for src-family tyrosine kinases. However,
attempts at reciprocal coimmunoprecipitation did not
reveal a detergent-resistant association between pyk2
and fgr, hck, or syk (data not shown).
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Table 1
Tyrosine kinase inhibitors tested for their effect on PMA- and TNF-stimulated
H2O2 production.
Group A
Daidzein
Hypericin
Tubercidin 5¢ -monophosphate
5,7-Dihydroxy-3-(4-hydroxyphenyl)-8-methoxy-4H-1-benzopyran-4-one
5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one
(3,4,5-Trihydroxybenzylidene)malononitrile
N-[2-(Methylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride
1-(5-Isoquinolinylsulfonyl)homopiperazine dihydrochloride
1-(5-Isoquinolinylsulfonyl)-2-methyl-piperazine
Phosphonic acid ([(acetyloxy)methoxy]-2-naphthalenylmethyl)-
bis([acetyloxy]methyl) ester
N-(2-aminoethyl)-N-hexyl-5-isoquinolinesulfonamide hydrochloride
Pseudohypericin
(s)-5-Isoquinolinesulfonicacid 4-[2-[(5-isoquinolinyl-sulfonyl)methylamino]-3-
oxo-3-(4-phenyl-1-piperazinyl)propyl]phenyl ester
N(4),N(6)-bis(Phenyl)-2-methyl-5-nitro-4,5,6-pyrimidinetriamine
Group B
bis-Tyrophostin
(–)-(s)-N-(a -Methylbenzyl)-3,4-dihydroxybenzylidenecyanoacetamide
3,5-Di-tert-butyl-4-hydroxybenzilidenecyanoacetamide
N-Phenyl-3,4-dihydroxybenzylidencyanoacetamide
3-Amino-2,4-dicyano-5-(3¢ ,4¢ ,5¢ -trihydroxyphenyl)penta-2,4-dienonitrile
N,N-Bis(2¢ -hydroxybenzyl)-3-aminosalicylic acid
a -Cyano-3,4-dihydroxycinnamamide
3,4-Dihydroxy-a -cyanothiocinnamide
10-(3-[1-Piperazinyl]propyl)-2-trifluoromethylphenothiazine dimaleate
Methyl 2,5-dihydroxycinnamate
Group C
(4-Methoxybenzylidene)malononitrile
N-(2¢ ,5¢ -Dihydroxybenzyl)-N-[2¢ -hydroxybenzyl)-3-aminosalicylic acid
N-(2¢ ,5¢ -Dihydroxybenzyl)-5-aminosalicylic acid
3-[1-(3-Dimethylaminopropyl)-indol-3-yl]-3-(indol-3-yl)-maleimide
Group D
N-Benzyl-3,4-dihydroxy-—cyanocinnamide
Methyl 2,5-dihydroxycinnamate
(4-Hydroxybenzyl)malononitrile
(6,7-Dimethoxyquinazolin-4-yl)-(3-bromophenyl)amine
N-[2-(4-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide dihydrochlo-
ride
Chelerythrine chloride
(+/–)1-(5-Isoquinolinesulfonyl)-3-methylpiperazine dihydrochloride
N-(2¢ -Guanidinoethyl)-5-isoquinolinesulfonamide dihydrochloride
N-(2-Aminoethyl)-5-chloro-1-naphthalenesulfonamide hydrochloride
1-(5-Isoquinolinylsulfonyl)piperazine hydrochloride
N-(2-Aminoethyl)-5-isoquinolinesulfonamide dihydrochloride
1-(5-Chloronaphthalene-1-sulfonyl)-1h-hexahydro-1,4-diazepine hydrochloride
1-(5-Iodonaphthalene-1-sulfonyl)-1h-hexahydro-1,4-diazepine hydrochloride
(s)-5-Isoquinolinesulfonicacid 4-[2-[(5-isoquinolinyl-sulfonyl)methylamino]-3-
oxo-3- (4-phenyl-1-piperazinyl)propyl]phenyl ester
4¢ -Amino-6-hydroxyflavone
2¢ ,4¢ ,6¢ -Trihydroxy-3-(4-hydroxyphenyl)propiophenone
N-(2,3-Dihydroxyindol)-3,4-dihydroxybenzylidenecyanoacetamide
N-(Ethylbenzyl)-3,4-dihydroxybenzylidenecyanoacetamide
N-(Butylbenzyl)-3,4-dihydroxybenzylidenecyanoacetamide
N-(3-Phenylpropyl)-3,4-dihydroxy-a -cyanocinnamide
(–)-(r)-n-(a -Methylbenzyl)-3,4-dihydroxybenzylidenecyanoacetamide
3,4-Dihydroxybenzylidene)malononitrile
3,5-bis/tert-Butyl/-4-hydroxybenzylidene malononitrile
Compounds tested for their effect on PMA- and TNF-stimulated H2O2 pro-
duction were subdivided into 5 groups as follows. Group A showed less than
50% inhibition of responses to both PMA and TNF at the highest tested con-
centration (7.7 m M). Group B showed 50% inhibition of responses to both
PMA and TNF at approximately equivalent concentrations. Group C showed
50% inhibition of the response to PMA at concentrations lower than those
causing 50% inhibition of the response to TNF. Group D showed 50% inhibi-
tion of the response to TNF at concentrations significantly lower than those
causing 50% inhibition of the response to PMA.
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Inhibition of neutrophil spreading by wortmannin and
tyrphostin A9. Both wortmannin and tyrphostin A9
inhibited TNF-induced spreading of adherent PMNs,
but in a different fashion (Figure 7). Cells pretreated
with wortmannin (10 nM) stayed mostly round after
TNF treatment, extending only 1 or 2 short
pseudopodia. In contrast, tyrphostin A9-treated cells
responded to TNF by extending filopodia several
micrometers long and began to flatten. Nonetheless,
their spreading was arrested compared with TNF-
stimulated cells treated with vehicle alone. Thus,
wortmannin and tyrphostin A9 both interfered with
TNF-induced cytoskeletal reorganization, but wort-
mannin appeared to act earlier in the sequence than
tyrphostin A9.
Discussion
The present experiments demonstrate that pyk2 is pres-
ent in primary human PMNs and that TNF triggers its
tyrosine phosphorylation and activation in adherent
cells; they also suggest that pyk2 plays an essential role
in the TNF-triggered respiratory burst. The delayed and
prolonged kinetic of pyk2’s tyrosine phosphorylation is
consistent with a downstream role in TNF signaling,
such as that leading to cytoskeletal reorganization. The
localization of pyk2 primarily to podosomes and focal
adhesions positions it for this role, and its TNF-induced
association with paxillin may be one manifestation of its
execution of this assignment.
Adhesion-controlled cell responsiveness to soluble
agonists has become a major paradigm in cell biology
and immunology to explain how matrix and soluble
signals combine to regulate cellular behavior and fate.
In PMNs, adhesion-dependent responses that are inde-
pendent of transcription and translation constitute an
important portion of what the cells contribute to the
survival of the organism as well as to its pathology.
Experiments with blocking antibodies and/or genetic
deficiency states have indicated that b 2 and b 3 integrins
play a major role in the adhesion-dependent responses
of PMNs (1, 33). It remains unknown, however, how
integrins signal in this setting and how their signals are
integrated with those elicited by soluble agonists. Both
PI3K action and protein tyrosine phosphorylation are
essential for physiological agonists to trigger secretion
from adherent human PMNs (5, 9, 31, 34). Pyk2 is the
only specific tyrosine kinase in PMNs shown to depend
on PI3K for its activation. Thus, a key action of PI3K
may be to engineer the activation of pyk2.
The observation that low-dose wortmannin interfered
with the initial stages of TNF-induced cell spreading and
blocked the TNF-induced tyrosine phosphorylation of
pyk2 suggested that PI3K acted early in the TNF signal-
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Figure 5
Tyrphostin A9 inhibits the TNF-induced respiratory burst of human PMNs and
TNF-induced tyrosine phosphorylation of pyk2 but not their bactericidal activ-
ity. (a) Inhibition of TNF-stimulated H2O2 release. PMNs were plated in FBS-
coated 96-well plates and preincubated for 30 minutes with the indicated
concentrations of tyrphostin A9. Cells were then unstimulated (–) or stimu-
lated (+) either with TNF (100 ng/mL; gray bars) or PMA (100 ng/mL; filled
bars), and H2O2 release was recorded 60 minutes later as mean ± SEM of trip-
licates. (b) Lack of inhibition of bacterial killing. PMNs were preincubated (30
minutes at 4°C) with 0 (filled squares) or 5 m M (open squares) tyrphostin A9
and then infected with 10% autologous serum-opsonized Salmonella typhimuri-
um. Cells were lysed at indicated times and CFUs were determined. Survival of
bacteria without PMNs is shown with 0 (filled circles) or 5 m M (open circles)
tyrphostin A9. Mean ± SEM of triplicates; most error bars fall within the sym-
bols. (c) PMNs were plated on FBS-coated plates, preincubated for 30 min-
utes in the presence or absence of tyrphostin A9 (2 m M), and then stimulat-
ed with TNF (250 ng/mL) or left untreated for 60 minutes, as indicated. Cell
lysates were immunoprecipitated (IP) with anti-pyk2 antibody. Total cell lysate
and immunoprecipitates were separated by reducing SDS-PAGE, transferred
to nitrocellulose, and Western blotted (WB) with anti-phosphotyrosine mAb
(top) or anti-pyk2 antibody (bottom) followed by ECL detection. Molecular
mass markers are indicated in kilodaltons.
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ing pathway and upstream of pyk2. However, wortman-
nin also blocked the TNF-induced respiratory burst
when added at the end of the lag period at a time when
cells were fully spread. This suggested that PI3K activity
was also required after cell spreading had advanced past
the relatively late point at which tyrphostin A9 could
interrupt it. The latter observation suggests an addi-
tional role for PI3K downstream of pyk2.
Soluble, inflammatory stimuli of PMNs increase the
affinity and number of b 2 integrins expressed at the cell
surface. This process is thought to be mediated in large
part by activation of PI3K (35). This could account for
the action of PI3K upstream of pyk2, insofar as integrin
activation is required to activate pyk2. PIP2 and PIP3
produced by PI3K can activate the serine protein kinase
Akt (36). Akt can phosphorylate and activate protein
kinase C and the phox47 component of the respirato-
ry burst oxidase (37). Syk associates with both CD18
and fgr in activated, adherent PMNs (38), and activa-
tion of syk in response to formylated peptide appears
to be required for cell spreading and paxillin phospho-
rylation (9). Binding of pyk2 to phosphorylated pax-
illin could help localize pyk2 to podosomes and focal
adhesions. We speculate that activated syk and/or src
kinases phosphorylate pyk2, and that phosphorylated
pyk2 provides binding sites in podosomes and focal
adhesions for additional molecules of PI3K. The ensu-
ing tyrosine phosphorylation of PI3K would lead to its
activation, membrane association, and further aug-
mentation of integrin activation. This scenario could
help explain why the long lag period in the TNF-stim-
ulated respiratory burst has features of a positive-feed-
back system, terminating abruptly with the release of
H2O2 at the maximal rate.
Defining the role of an enzyme within primary
human neutrophils is more difficult than in many
other types of cells. Neutrophils are not amenable to
transfection. They cannot be loaded with presumptive
dominant-negative peptides by osmotic shock or elec-
troporation if the goal is to follow the cells’ response to
physiological agonists over subsequent hours.
Leukemic cell lines such as HL-60 can respond to PMA
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Figure 6
Wortmannin inhibits the TNF-induced respiratory
burst and tyrosine phosphorylation of pyk2. (a) H2O2
release from PMNs measured 120 minutes after the
addition of TNF (100 ng/mL; squares) or PMA (100
ng/mL; circles). Wortmannin (10 nM) was added to
separate sets of cells at the indicated number of min-
utes after TNF or PMA. Results are mean ± SEM for
triplicates in 1 experiment of 3; some error bars fall
within the symbols. (b) Tyrosine phosphorylation.
PMNs were plated on FBS-coated plates and treated
for 60 minutes with buffer alone or TNF (100 ng/mL)
in the presence or absence of wortmannin (Wort) at
10 nM or the src kinase inhibitor PP2 (2.5 m M) as
indicated. Cell lysates were immunoprecipitated (IP)
with anti-pyk2 antibody. Total cell lysate (top) and
anti-pyk2 immunoprecipitates (bottom) were sepa-
rated by reducing SDS-PAGE, transferred to nitrocel-
lulose, and Western blotted (WB) with anti-phos-
photyrosine mAb followed by ECL detection.
Molecular mass markers are indicated in kilodaltons.
Figure 7
Wortmannin and tyrphostin A9 inhibit TNF-induced neutrophil spreading. PMNs adherent to FBS-coated glass coverslips were left untreat-
ed (a) or stimulated with TNF (100 ng/mL) for 60 minutes (b–d), either alone (b) or in the presence of wortmannin (10 nM) (c) or tyrphostin
A9 (2 m M) (d), and then fixed and photographed with phase-contrast microscopy.
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but do not manifest a TNF-stimulated respiratory
burst after differentiation. Primary mouse neutrophils
are genetically manipulatable through the germ line,
but their TNF-induced respiratory burst is about 20-
fold smaller than in human neutrophils (11) and, in
our laboratory, has been detectable in only a small pro-
portion of experiments; responses to a formylated pep-
tide have been completely lacking (data not shown).
As an alternative to genetic intervention, we took a
pharmacologic approach, surveying 51 tyrosine kinase
inhibitors. We sought compounds at least equal in
potency to those already shown to be inhibitory of the
integrin-dependent, TNF-induced respiratory burst (6)
and inactive against the response triggered by phorbol
ester, which is integrin independent (1). Tyrphostin A9
was previously identified as a relatively selective
inhibitor of the tyrosine kinase activity of the PDGF
receptor, with an IC50 (40 nM) similar to that recorded
in the present experiments (39). The potency of tyr-
phostin A9 on PMNs matches that of K252a, the most
potent tyrosine kinase inhibitor of the TNF-induced
respiratory burst yet described (IC50 = 30 nM), and
exceeds by far the potency of others previously studied
(genistein, IC50 = 10 m M; ST638, IC50 = 30 m M; piceatan-
nol, IC50 = 1–10 m M) (5, 9). Tyrphostin A9’s inhibition
was relatively selective, sparing not only the PMA-
induced respiratory burst but also the ability of the
PMNs to ingest and kill bacteria. This illustrates the
potential to exert an anti-inflammatory action without
blocking intracellular bactericidal function.
Identification of the steps proximal and distal to
pyk2 in the TNF- and adhesion-dependent responses
of human PMNs may reveal relatively myeloid-specific,
enzymatic targets for anti-inflammatory therapy.
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